Trevor Clancy new group leader in Cancer Systems Biomedicine

Statement from Kjetil Taskén, Institute head:

As part of the new ICR strategy for Cancer Systems Biomedicine and Bioinformatics developed in 2023, we advertised two positions, one at the Department of Molecular Oncology (filled) and one at the Department of Tumor Biology (coupled to an adjunct Associate Professor position).

The 25 applicants for the position at the Department of Tumor Biology were evaluated by an international scientific committee. After interviews with the four top candidates, the position was offered to Trevor Clancy, who has today resumed the position as Group Leader in Cancer Systems Biomedicine.

Trevor is a cancer bioinformatics scientist with over 20 years of experience in bioinformatics, cancer research and biotechnology. He was mentored by Eivind Hovig during his PhD and postdoctoral fellowship, and later worked with Kalle Malmberg in a senior scientist position. Trevor has focused on integrating multi-omics, tumor–immune biology and AI to generate clinically meaningful insight. He co-founded OncoImmunity (later NEC OncoImmunity following its acquisition by the multinational NEC Corporation) and, as Chief Scientific Officer and leading senior scientist, spearheaded AI-driven personalized cancer immunotherapy projects. His overarching goal now is to develop robust AI-based tools, such as tumor avatars, that improve cancer prevention, therapy selection and patient outcomes

Please welcome Trevor as a Group Leader.

Links:

The Cancer Systems Biomedicine research group, headed by Trevor Clancy

Department of Tumor Biology

Institute for Cancer Research